BiotechTube
Home/Vivazome/Xenia Sango
XS

Xenia Sango

Chief Executive Officer & Managing Director

Vivazome

Therapeutic Areas

NeurologyNeurodegeneration

Vivazome Pipeline

DrugIndicationPhase
VivaZome TBI TherapyTraumatic Brain Injury (including Post‑Traumatic Epilepsy)Preclinical
VivaZome Stroke TherapyAcute and Chronic StrokePreclinical
VivaZome Tauopathy TherapyNeurodegenerative diseases (tauopathies, dementia)Preclinical

Leadership Team at Vivazome

AF
Anthony Filippis
Non‑Executive Director
CN
Craig Newton
Non‑Executive Director
DH
David Haylock
Chief Scientific Officer
View full Vivazome profile